News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

THERAVECTYS is Granted Authorization From the French and Belgian Regulatory Agencies to Launch a Phase I/Ii Clinical Trial for Its Anti-HIV Therapeutic Vaccine Candidate


11/30/2012 11:46:41 AM

PARIS--(BUSINESS WIRE)--THERAVECTYS, a French biotechnology company currently developing a new generation of vaccines, today announced it was granted authorization by the National Security Agency for Medicines and Health Products in France (Agence Nationale de Sécurité du Médicament et des produits de santé) and the Federal Agency for Medicines and Health Products in Belgium (Agence Fédérale des Médicaments et des Produits de Santé) to launch a phase I/II clinical trial for its anti-HIV therapeutic vaccine candidate based on lentiviral vector technology.

Read at BioSpace.com

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES